The measurement of bronchial reactivity in epidemiological studies has the advantage of quantifying an objective physiological feature of asthma. Bronchial reactivity was developed in a clinical setting and has been conventionally expressed as the dose of agonist producing a 20% fall in FEV1(PD20). As PD20 can be estimated for less than 20% of subjects in general community surveys with the doses of agonist that are usually given, data from most subjects must be censored. Thus PD20 alone is a poor index of bronchial reactivity for epidemiological studies. Data from 809 aluminium smelter workers were used to evaluate alternative methods of analysing bronchial reactivity. Dose-response relationships were analysed by four methods: (1) PD20 by the conventional method of interpolating the dose on a logarithmic scale between the last two measurements of FEV,; (2) PD20 (with allowance for extrapolation), estimated by fitting an exponential curve to the dose-response data; (3) the linear regression slope between dose and FEV1 when significant; (4) the dose-response slope obtained in all subjects as the % change in FEV, from baseline in response to total dose. When each of these measures was related to symptoms, diagnosis, and treatment of asthma, all differentiated between "asthmatic" and "non-asthmatic" subjects. The dose-response slope (method 4) had the advantages of simplicity and no censored data, and was shown to be clinically relevant. It is suggested that the dose-response slope should be used for the analysis of bronchial reactivity in epidemiological studies.
Bronchial reactivity or responsiveness is both an important physiological outcome and a quantifiable feature of asthma. Epidemiological studies have investigated its distribution in general community surveys conducted in Australia, '13 Because PD20 can be estimated in only a minority of subjects in community surveys, it is not an ideal measure of bronchial reactivity for epidemiological research. To describe the distribution of bronchial reactivity in a healthy population completely requires a continuously distributed index that summarises the dose-response data for all individuals.
The slope of the dose-response line has been investigated in laboratory studies as an alternative index of bronchial reactivity.9-" These studies have all included substantial numbers of asthmatic subjects, however, and have not considered the value of slope coefficients in epidemiological studies. Empirical evidence9 12 favours the use of a linear rather than a logarithmic dose scale. In the present study of aluminium workers two methods for deriving PD20 were compared and alternative indices of bronchial reactivity evaluated.
Methods
The subjects were participants in a longitudinal study of respiratory symptoms and lung function in aluminium smelter workers. After giving informed consent, 809 (96%) of the 843 male employees completed a methacholine challenge, in which they inhaled increasing doses up to [6] [7] [8] [9] [10] [11] [12] [13] [14] After the administration of 6-14 gmol methacholine FEV1 increased from baseline in 123 (15%) subjects, showed no change in 21 (3%), a decrease of less than 10% in 509 (63%), and a decrease of 10-20% in 91 (11 %) subjects. Only 65 (8%) subjects had a decline in FEV1 of more than 20%. For these 65 cases PD20 was inter- those who did not report such features (table 5) . Means values of interpolated PD20 were significantly lower in subjects with a history of asthma and in those who used salbutamol. Mean values of "exponential" PD20 and the inverse cube root of the slope were also significantly lower in subjects who wheezed; mean log dose-response slope was significantly higher in subjects with any of these features. The indices of separation (D/s) indicated that log dose-response slope best separated asthmatic from non-asthmatic individuals; the inverse cube root of the slope was less efficient, and there was greatest overlap for PD20.
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The quantities are dimensionless.
REPRODUCIBILITY
The reproducibility or repeatability of bronchial reactivity indices were assessed by measurement of agreement between indices for the same subjects on rechallenge. The intraclass correlation coefficients are listed for interpolated and exponential PD20, inverse cube root of the slope, and log dose-response slope in The apparent improvement in FEV1 with increasing doses of methacholine, seen in 15% of our subjects, has been reported previously. '6 It might be an effect of practice or a consequence of slight stiffening of the central airways with agonist administration moving the equal pressure (choke) point downstream. It is also possible that a decline in FEVy with increasing doses of methacholine could occur from fatigue rather than bronchoconstriction. Subjects had at least two minutes, however, to recover between blows. The reproducibility of bronchial reactivity makes it very unlikely that fatigue is causing a dose related reduction in FEV,.
The usual clinical method of estimating PD20 from interpolation between the last two measurements fails to obtain data from most normal subjects. It provided an index of bronchial reactivity for only 8% of this occupational sample. The use of a higher dose of agonist might have provided more subjects with an interpolated PD20 as well as information on a plateau response;23 but as subjects had to return to work after being tested we did not think it appropriate to explore maximal responses to methacholine.
The exponential algorithm yields an estimate for PD20 in less than half the number of cases for which simple linear regression yields a significant slope. It has the disadvantage of estimating three parameters from five data points. Extrapolation beyond the dose administered is potentially hazardous for a non-linear function with no estimate of error variance. The results agree well, however, with the conventional interpolated estimate of PD20.
The Fortran program operates rapidly and efficiently on a computer.
In summary, the exponential algorithm uses In any case, such influence could be considered biologically appropriate as most ofthe response occurred at higher doses.
The inverse cube root of the slope had the desirable biological and statistical property of being normally distributed, was reproducible, and had clinical validity. The inverse cube root scale is unusual, but not entirely without parallel in respiratory epidemiology. For instance, the latent period for the development of respiratory cancer appears to be related to the inverse cube root of asbestos dose. 25 The inverse cube root of the slope is interpreted in the same manner as PD20 in that the larger the value the less reactive the subject. There was excellent agreement between PD20 and the cube root of the slope measurements, and subjects lacking an estimate of PD20 had significantly greater values for the inverse cube root of the slope. Subjects with slope alone have measurable reactivity, but of a lesser degree than those with both slope and PD20. This was confirmed by the differences in mean log dose-response slope.
The most widely applicable index of bronchial reactivity is the dose-response slope, which could be calculated for all subjects. The single parameter is simple to calculate and agrees well with the slope from linear regression, as has been previously found.1' This model does, however, assume that the first and last measurements of FEV, were made without error, which is unlikely, and the absence of any test of statistical significance means that all subjects contribute a dose-response slope and this will include random noise. Subjects showing an increase in FEV, from its post-saline baseline to the final dose of methacholine are certainly less reactive than those who show a decrease, but they may differ little from those whose FEV, shows little or not change. Thus assignment of a number to their lack of reactivity is hard to justify. Despite the incorporation of data from such subjects log doseresponse slope was highly reproducible.
Although the distribution of log dose-response slope was not normal, log transformation allowed bronchial reactivity to be expressed on a familiar logarithmic scale. The increment for eliminating negative and zero values before log transformation requires standardisation. The previously suggested 03%/gimol" would have been insufficient in the present study. Alternatively, untransformed dose-response slope values could be analysed by non-parametric statistical tests, which are sufficiently robust not to be unduly influenced by the severely skewed distribution.
In conclusion, measuring the dose-response slope has the advantages of simplicity, reproducibility, clinical validity, and absence of censored data. Neither exponential PD20 nor the inverse cube root of the slope combines these desirable features in a single index. We would recommend using the dose-response slope for analysis of bronchial reactivity in future epidemiological studies.
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